iBio (IBIO) EBIT Margin (2011 - 2025)

iBio (IBIO) posted quarterly EBIT Margin of 5951.0% for Q3 2025, down 128.97% quarter-over-quarter from 2599.0% in Q2 2025.

iBio (IBIO) EBIT Margin (2011 - 2025) Analysis & Trends

iBio (IBIO) has reported EBIT Margin for 15 consecutive years, with 5951.0% the latest figure, recorded in Q3 2025.

In Q3 2025, EBIT Margin changed N/A year-over-year to 5951.0%; the TTM figure through Mar 2026 stood at 9653.0% (down 516953.0% YoY), while the FY2025 annual figure was 4650.5%, up 274239.0% from the prior year.
EBIT Margin slipped to 5951.0% in Q3 2025 per IBIO's latest filing, from 2599.0% in the prior quarter.
Across five years, EBIT Margin topped out at 377.11% in Q1 2022 and bottomed at 10206.0% in Q3 2023.
Historically, EBIT Margin has averaged 3597.2% across 5 years, with a median of 2209.5% in 2024.
On a YoY basis, EBIT Margin climbed as much as 329176 bps in 2021 and fell as far as 453146 bps in 2021.
iBio's EBIT Margin stood at 6220.24% in 2021, then surged by 94 bps to 377.11% in 2022, then slumped by 2606 bps to 10206.0% in 2023, then surged by 78 bps to 2209.5% in 2024, then plunged by 169 bps to 5951.0% in 2025.
Business Quant data shows IBIO's EBIT Margin at 5951.0% in Q3 2025, 2599.0% in Q2 2025, and 2209.5% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	iBio	175.21 Mn	175.21 Mn	-	-

Download Data